Clinical Trial Update: Once-A-Month Steroid Treatment for Patients With Focal Segmental Glomerulosclerosis [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating once-a-month steroid treatment for focal segmental glomerulosclerosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Focal Segmental Glomerulosclerosis
• Glomerulonephritis
• Nephrotic Syndrome

Snippet

Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Conditions: Glomerulonephritis, Nephrotic Syndrome | Phase 2 | Status: COMPLETED